Piramal Pharma Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Piramal's expertise across varied technologies makes them a partner of choice for innovators & generic companies worldwide.
One of their notable products is CLOBAZAM, with a corresponding US DMF Number 29164.
Remarkably, this DMF maintains an Active status since its submission on March 28, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 02, 2016, and payment made on September 24, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II